The clinical burden of allergic rhinitis in five Middle Eastern countries: results of the SNAPSHOT program

Ahmed Al-Digheari, Bassam Mahboub, Hesham Tarraf, Taskin Yucel, Isabella Annesi-Maesano, Adam Doble, Aaicha Lahlou, Luqman Tariq, Fayaz Aziz, Abdelkader El Hasnaoui, Ahmed Al-Digheari, Bassam Mahboub, Hesham Tarraf, Taskin Yucel, Isabella Annesi-Maesano, Adam Doble, Aaicha Lahlou, Luqman Tariq, Fayaz Aziz, Abdelkader El Hasnaoui

Abstract

Background: The SNAPSHOT program provides current data on the allergic rhinitis burden in the adult general population of five Middle Eastern countries (Egypt, Turkey, Kuwait, Saudi Arabia and the United Arab Emirates, the latter three grouped into a Gulf cluster).

Methods: A multi-country, cross-sectional, epidemiological program conducted by telephone in a random sample of the adult general population; quotas were defined per country demographics. Subjects were screened for allergic rhinitis using the Score For Allergic Rhinitis questionnaire. Current prevalence (last 12 months) was estimated. Disease severity and control were assessed using the Allergic Rhinitis and its Impact on Asthma classification and Rhinitis Control Assessment Test respectively. Quality of sleep, impact on daily activities and quality of life were measured using the Epworth Sleepiness Scale, Sheehan Disability Scale and EuroQol Five-Dimension questionnaire respectively. Multivariate logistic regression analyses were used to investigate risk factors and co-morbidities.

Results: 1808 of 33,486 subjects enrolled in the SNAPSHOT program fulfilled the case definition for allergic rhinitis. Prevalence was 3.6% [95% CI 3.2-4.0%] in Egypt, 6.4% [95% CI 5.9-6.9%] in Turkey and 6.4% [95% CI 6.0-6.9%] in the Gulf cluster. Risk factors identified were country, co-morbid asthma and income. Subjects with allergic rhinitis reported a significantly lower quality of life compared to the general population (p < 0.0001). Overall, 55% of allergic rhinitis subjects were moderate/severe and 33% were uncontrolled. Both these groups reported impaired quality of life and quality of sleep and increased impairment of daily activities compared to mild/well-controlled subjects (p < 0.0001).

Conclusions: Although the observed prevalence of allergic rhinitis in these Middle Eastern countries is low compared to western countries, its burden is considerable. Allergic rhinitis in general, and specifically uncontrolled and severe disease, results in a negative impact on quality of life, quality of sleep and daily activities.

Keywords: Allergic rhinitis; Clinical burden; Middle East; Quality of life; SNAPSHOT.

Figures

Fig. 1
Fig. 1
Risk factors for allergic rhinitis. Multivariate regression analysis investigating the risk factors for allergic rhinitis (AR): AR population (1679 subjects) versus non-AR population (28,351 subjects); OR [95% CI] = odds ratio [95% confidence interval]. The results presented are adjusted for age (18–34, 35–49, ≥ 50 years), gender and country (Egypt, Kuwait, Saudi Arabia, Turkey, UAE)
Fig. 2
Fig. 2
Impact of co-morbidities on the risk of allergic rhinitis. Multivariate regression analysis investigating the impact of co-morbidities. Allergic rhinitis (AR) population (1808 subjects) versus non-AR population (31,678 subjects); OR [95% CI] = odds ratio [95% confidence interval]. The results presented are adjusted for age (18–34, 35–49, ≥ 50 years), gender and country (Egypt, Kuwait, Saudi Arabia, Turkey, UAE)
Fig. 3
Fig. 3
Impact of allergic rhinitis on quality of life. Quality of life was assessed using the three level EuroQol Five Dimension questionnaire (EQ-5D-3L) a EQ-5D-3L utility values for the allergic rhinitis (AR) population and general population by country b EQ-VAS scores for the AR population and general population by country. For the AR population (n = 1808) the data represent the mean EQ-5D-3L utility value and EQ-VAS score with the 95% CI. For the general population (n = 33,486), the mean EQ-5D-3L utility value and EQ-VAS score is presented. The p values were calculated using the Kruskall–Wallis test. Permission to use the EQ-5D-3L was provided by the EuroQol Research Foundation (© EuroQol Research Foundation. EQ-5D™ is a trade mark of the EuroQol Research Foundation)
Fig. 4
Fig. 4
Impact of allergic rhinitis control and disease severity on daily life. Impact of allergic rhinitis control and disease severity on activities of daily living a impact of disease severity based on the allergic rhinitis and its impact on asthma (ARIA) classification on activities of daily living, assessed using the Sheehan Disability Scale (SDS) b impact of AR control measured using the Rhinitis Control Assessment Test (RCAT) on activities of daily living measured using the SDS. The p values were calculated using the X2 test
Fig. 5
Fig. 5
Impact of allergic rhinitis control on daytime sleepiness. Impact of AR control measured using the Rhinitis Control Assessment Test (RCAT) on reported levels of daytime sleepiness, measured by the Epworth Sleepiness Scale (ESS). The p value was calculated using the X2 test

References

    1. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, Zuberbier T, Baena-Cagnani CE, Canonica GW, van Weel C, et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen) Allergy. 2008;63(Suppl 86):8–160. doi: 10.1111/j.1398-9995.2007.01620.x.
    1. Leger D, Annesi-Maesano I, Carat F, Rugina M, Chanal I, Pribil C, El Hasnaoui A, Bousquet J. Allergic rhinitis and its consequences on quality of sleep: an unexplored area. Arch Intern Med. 2006;166:1744–1748. doi: 10.1001/archinte.166.16.1744.
    1. Blanc PD, Trupin L, Eisner M, Earnest G, Katz PP, Israel L, Yelin EH. The work impact of asthma and rhinitis: findings from a population-based survey. J Clin Epidemiol. 2001;54:610–618. doi: 10.1016/S0895-4356(00)00349-8.
    1. Marshall PS, O’Hara C, Steinberg P. Effects of seasonal allergic rhinitis on fatigue levels and mood. Psychosom Med. 2002;64:684–691.
    1. Marshall PS, O’Hara C, Steinberg P. Effects of seasonal allergic rhinitis on selected cognitive abilities. Ann Allergy Asthma Immunol. 2000;84:403–410. doi: 10.1016/S1081-1206(10)62273-9.
    1. Bedolla-Barajas M, Morales-Romero J, Pulido-Guillen NA, Robles-Figueroa M, Plascencia-Dominguez BR. Rhinitis as an associated factor for anxiety and depression amongst adults. Braz J Otorhinolaryngol. 2017;83:432–438. doi: 10.1016/j.bjorl.2016.05.008.
    1. Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J. 2004;24:758–764. doi: 10.1183/09031936.04.00013904.
    1. Nathan RA, Meltzer EO, Derebery J, Campbell UB, Stang PE, Corrao MA, Allen G, Stanford R. The prevalence of nasal symptoms attributed to allergies in the United States: findings from the burden of rhinitis in an America survey. Allergy Asthma Proc. 2008;29:600–608. doi: 10.2500/aap.2008.29.3179.
    1. Mahboub B, Al-Hammadi S, Prakash VP, Sulaiman N, Blaiss MS, Redha AA, Vats DM. Prevalence and triggers of allergic rhinitis in the United Arab Emirates. World Allergy Organ J. 2014;7:19. doi: 10.1186/1939-4551-7-19.
    1. Sakar A, Yorgancioglu A, Dinc G, Yuksel H, Celik P, Dagyildizi L, Coskun E, Kaya E, Ozyurt B, Ozcan C. The prevalence of asthma and allergic symptoms in Manisa, Turkey (A western city from a country bridging Asia and Europe) Asian Pac J Allergy Immunol. 2006;24:17–25.
    1. Dinmezel S, Ogus C, Erengin H, Cilli A, Ozbudak O, Ozdemir T. The prevalence of asthma, allergic rhinitis, and atopy in Antalya, Turkey. Allergy Asthma Proc. 2005;26:403–409.
    1. Kurt E, Metintas S, Basyigit I, Bulut I, Coskun E, Dabak S, Deveci F, Fidan F, Kaynar H, Kunt Uzaslan E, et al. Prevalence and risk factors of allergies in Turkey (PARFAIT): results of a multicentre cross-sectional study in adults. Eur Respir J. 2009;33:724–733. doi: 10.1183/09031936.00082207.
    1. Cingi C, Songu M, Ural A, Annesi-Maesano I, Erdogmus N, Bal C, Kahya V, Koc EA, Cakir BO, Selcuk A, et al. The score for allergic rhinitis study in Turkey. Am J Rhinol Allergy. 2011;25:333–337. doi: 10.2500/ajra.2011.25.3665.
    1. El Hasnaoui A, Aziz F, Tariq L, Lahlou A, Du Plessis D. An omnibus approach to assess the prevalence, burden and quality of life of multiple diseases in the general population: the SNAPSHOT program in the Middle East. Med Res Arch. 2018;6(2)
    1. EuroQol Group EuroQol–a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199–208. doi: 10.1016/0168-8510(90)90421-9.
    1. Brooks R. EuroQol: the current state of play. Health Policy. 1996;37:53–72. doi: 10.1016/0168-8510(96)00822-6.
    1. Annesi-Maesano I, Didier A, Klossek M, Chanal I, Moreau D, Bousquet J. The score for allergic rhinitis (SFAR): a simple and valid assessment method in population studies. Allergy. 2002;57:107–114. doi: 10.1034/j.1398-9995.2002.1o3170.x.
    1. Piau JP, Massot C, Moreau D, Ait-Khaled N, Bouayad Z, Mohammad Y, Khaldi F, Bah-Sow O, Camara L, Koffi NB, et al. Assessing allergic rhinitis in developing countries. Int J Tuberc Lung Dis. 2010;14:506–512.
    1. Waibel KH. Allergic rhinitis in the Middle East. Mil Med. 2005;170:1026–1028. doi: 10.7205/MILMED.170.12.1026.
    1. Rabe KF, Adachi M, Lai CK, Soriano JB, Vermeire PA, Weiss KB, Weiss ST. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol. 2004;114:40–47. doi: 10.1016/j.jaci.2004.04.042.
    1. Schatz M, Meltzer EO, Nathan R, Derebery MJ, Mintz M, Stanford RH, Dalal AA, Silvey MJ, Kosinski M. Psychometric validation of the rhinitis control assessment test: a brief patient-completed instrument for evaluating rhinitis symptom control. Ann Allergy Asthma Immunol. 2010;104:118–124. doi: 10.1016/j.anai.2009.11.063.
    1. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14:540–545. doi: 10.1093/sleep/14.6.540.
    1. Sheehan KH, Sheehan DV. Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale. Int Clin Psychopharmacol. 2008;23:70–83. doi: 10.1097/YIC.0b013e3282f2b4d6.
    1. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol. 1996;11(Suppl 3):89–95. doi: 10.1097/00004850-199606003-00015.
    1. Min SY, Park DW, Yun SC, Kim YH, Lee JY, Kang SJ, Lee SW, Lee CW, Kim JJ, Park SW, Park SJ. Major predictors of long-term clinical outcomes after coronary revascularization in patients with unprotected left main coronary disease: analysis from the MAIN-COMPARE study. Circ Cardiovasc Interv. 2010;3:127–133. doi: 10.1161/CIRCINTERVENTIONS.109.890053.
    1. Alsowaidi S, Abdulle A, Shehab A, Zuberbier T, Bernsen R. Allergic rhinitis: prevalence and possible risk factors in a Gulf Arab population. Allergy. 2010;65:208–212. doi: 10.1111/j.1398-9995.2009.02123.x.
    1. Abdulrahman H, Hadi U, Tarraf H, Gharagozlou M, Kamel M, Soliman A, Hamad WA, Hanna KM, Mostafa BE, Omrani M, et al. Nasal allergies in the Middle Eastern population: results from the “Allergies in Middle East Survey”. Am J Rhinol Allergy. 2012;26(Suppl 1):S3–S23. doi: 10.2500/ajra.2012.26.3836.
    1. Cingi C, Topuz B, Songu M, Kara CO, Ural A, Yaz A, Yildirim M, Miman MC, Bal C. Prevalence of allergic rhinitis among the adult population in Turkey. Acta Otolaryngol. 2010;130:600–606. doi: 10.3109/00016480903311880.
    1. Basak O, Basak S, Gultekin B, Tekin N, Soylemez A. The prevalence of allergic rhinitis in adults in Aydin, Turkey. Rhinology. 2006;44:283–287.
    1. Colas C, Galera H, Anibarro B, Soler R, Navarro A, Jauregui I, Pelaez A. Disease severity impairs sleep quality in allergic rhinitis (The SOMNIAAR study) Clin Exp Allergy. 2012;42:1080–1087. doi: 10.1111/j.1365-2222.2011.03935.x.
    1. Bhattacharyya N. Functional limitations and workdays lost associated with chronic rhinosinusitis and allergic rhinitis. Am J Rhinol Allergy. 2012;26:120–122. doi: 10.2500/ajra.2012.26.3752.
    1. Meltzer EO, Blaiss MS, Naclerio RM, Stoloff SW, Derebery MJ, Nelson HS, Boyle JM, Wingertzahn MA. Burden of allergic rhinitis: allergies in America, Latin America, and Asia-Pacific adult surveys. Allergy Asthma Proc. 2012;33(Suppl 1):S113–S141. doi: 10.2500/aap.2012.33.3603.
    1. Bousquet J, Neukirch F, Bousquet PJ, Gehano P, Klossek JM, Le Gal M, Allaf B. Severity and impairment of allergic rhinitis in patients consulting in primary care. J Allergy Clin Immunol. 2006;117:158–162. doi: 10.1016/j.jaci.2005.09.047.
    1. Stuck BA, Czajkowski J, Hagner AE, Klimek L, Verse T, Hormann K, Maurer JT. Changes in daytime sleepiness, quality of life, and objective sleep patterns in seasonal allergic rhinitis: a controlled clinical trial. J Allergy Clin Immunol. 2004;113:663–668. doi: 10.1016/j.jaci.2003.12.589.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere